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ABSTRACT
Approximately 1 in 3–4 patients presenting
with an ischemic stroke will also have atrial
fibrillation (AF), and AF-related strokes can be
effectively prevented using oral anticoagulant
therapy (OAC), either with well-controlled
vitamin K antagonists (VKAs) or non-vitamin
K antagonist oral anticoagulants (NOACs). In
addition, OAC use (both VKAs and NOACs) is
associated with a 26% reduction in all-cause
mortality (VKAs) or an additional 10%
mortality reduction with NOACs relative to
VKAs. The decision to use OAC in individual
AF patient is based on the estimated balance of
the benefit from ischemic stroke reduction
against the risk of major OAC-related bleeding
[essentially intracranial hemorrhage (ICH)].
Better appreciation of the importance of VKAs’
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Vascular Surgery Clinic, Clinical Centre, Belgrade,
Serbia
F. Marin
Department of Cardiology, Hospital Universitario
Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain
L. Fauchier
Service de Cardiologie, Centre Hospitalier
Universitaire Trousseau et Faculte de Medecine,
Universite Francois Rabelais, Tours, France
C. Blomstrom-Lundqvist
Department of Cardiology, Institution of Medical
Science, Uppsala University, Uppsala, Sweden
G. Y. H. Lip
University of Birmingham Institute of
Cardiovascular Science, City Hospital, Birmingham,
UK
G. Y. H. Lip
Aalborg Thrombosis Research Unit, Department of
Clinical Medicine, Aalborg University, Aalborg,
Denmark
Adv Ther (2017) 34:357–377
DOI 10.1007/s12325-016-0458-7
anticoagulation quality [a target time in
therapeutic range (TTR) of C70%] and the
availability of NOACs (which offer better
safety compared to VKAs) have decreased the
estimated threshold for OAC treatment in AF
patients towards lower stroke risk levels. Still,
contemporary registry-based data show that
OAC is often underused in AF patients at
increased risk of stroke. The uncertainty
whether to use OAC may be particularly
pronounced in AF patients with a single
additional stroke risk factor, who are often
(mis)perceived as having a ‘‘borderline’’ or
insufficient stroke risk to trigger the use of
OAC. However, observational data from
real-world AF cohorts show that the annual
stroke rates in such patients are higher than in
patients with no additional stroke risk factors,
and OAC use has been associated with
reduction in stroke, systemic embolism, or
death in comparison to no therapy or aspirin,
with no increase in the risk of bleeding relative
to aspirin. In this review article, we summarize
the basic principles of stroke risk stratification
in AF patients and discuss contemporary
real-world evidence on OAC use and outcomes
of OAC treatment in AF patients with a single
additional stroke risk factor in various
real-world AF cohorts.
Keywords: Atrial fibrillation; Non-valvular
atrial fibrillation; Non-vitamin K antagonist;
Oral anticoagulants; Stroke prevention; Stroke
risk assessment; Stroke risk factor; Stroke risk
scores; Vitamin K antagonist
INTRODUCTION
Atrial fibrillation (AF) currently affects at least
33.5 million adults in the world population, not
including subclinical or undiagnosed AF cases
[1, 2], and the global prevalence of documented
AF is probably underestimated because of
limited data outside Europe and North
America [1, 3].
Recent population-based studies and stroke
registries consistently report a substantial
AF-attributable risk of stroke, particularly in
the elderly [4]. Approximately 1 in 3–4 patients
presenting with an ischemic stroke will also
have AF (either already known or first diagnosed
at the time of acute stroke, or documented
during the post-stroke monitoring) [4, 5]. In
comparison to strokes from other causes,
AF-related strokes are more often fatal or
associated with greater permanent
neurological deficit [6], but can be effectively
prevented using oral anticoagulant therapy
(OAC) with well-controlled vitamin K
antagonists (VKAs) [7] or non-vitamin K
antagonist oral anticoagulants (NOACs)
apixaban [8], rivaroxaban [9], dabigatran [10],
or edoxaban [11]. The use of OAC is also
associated with significant reduction in
all-cause mortality in AF patients, by 26% with
VKAs vs. control/placebo [7], and by additional
10% risk reduction with NOACs relative to
warfarin according to meta-analysis [12].
The decision to use OAC in individual AF
patient is based on the estimated balance of the
benefit from ischemic stroke reduction against
the risk of major OAC-related bleeding
[essentially intracranial hemorrhage (ICH)].
Better appreciation of the importance of VKAs’
anticoagulation quality [a target time in
therapeutic range (TTR) of C70%] and the
availability of NOACs (which offer better
safety compared to VKAs) [12] have decreased
the estimated threshold for OAC treatment in
AF patients from 1.7% (as estimated for the
VKAs standard treatment) to 0.9% annual
stroke risk, assuming that NOACs are available
[13].
358 Adv Ther (2017) 34:357–377
Still, contemporary registry-based data show
that OAC is often underused in AF patients at
increased risk of stroke [14–18]. The uncertainty
whether to use OAC may be particularly
pronounced in AF patients with a single
additional stroke risk factor, who are often
(mis)perceived as having a ‘‘borderline’’ or
insufficient stroke risk to trigger the use of
OAC. Also, there is some inconsistency in
formal AF guidelines regarding the use of OAC
in this subset of AF patients, as shown in Table 1
[19–25].
In this review article, we summarize the basic
principles of stroke risk stratification in AF
patients and discuss contemporary real-world
evidence on OAC use and outcomes of OAC
treatment in AF patients with a single
additional stroke risk factor in various
real-world AF cohorts. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
STROKE RISK STRATIFICATION
AND THROMBOPROPHYLAXIS
IN PATIENTS WITH ATRIAL
FIBRILLATION
Patients with AF have an excessive risk of stroke
compared to their counterparts without AF but
individual stroke risk is not homogeneous and
depends on the presence (or absence) of various
stroke risk factors [26]. To facilitate the
assessment of AF-related risk of stroke in
clinical practice, established clinical stroke risk
factors derived from the control or placebo arms
of historical trials on stroke prevention in AF [7]
or large observational AF cohorts have been
combined into various stroke risk scores, such as
the CHADS2 or CHA2DS2-VASc score [27]
(Table 2), the latter being more inclusive of
relevant clinical stroke risk factors in
comparison to the CHADS2 score [28, 29].
Although simple, the CHADS2 score has
well-recognized limitations [30] including poor
identification of AF patients at truly low risk of
stroke. For example, it has been shown that
patients with a CHADS2 of 0 (presumably
low-risk patients) have had an annual stroke
rate as high as 3.2% [28].
The CHA2DS2-VASc score has been validated
in a number of independent cohorts
[28, 31–35], and is the recommended tool for
stroke risk assessment in most of the latest
formal AF guidelines [20, 24]. Compared to
other AF-related stroke risk scores,
CHA2DS2-VASc is reasonably simple, which is
necessary for widespread use in routine clinical
practice, and performs well, especially in
reliable identification of AF patients at truly
low risk of stroke (i.e., those with no additional
stroke risk factors) who do not need any
thromboprophylaxis [28, 36–39]. Recent
comparisons of the more complex ATRIA score
against the CHA2DS2-VASc score yielded
conflicting results, although CHA2DS2-VASc
generally outperforms the ATRIA score for risk
prediction [35, 37, 40, 41]. Of note, the ATRIA
score includes the indices of renal function (i.e.,
estimated glomerular filtration rate and
proteinuria), which may not be readily
available in a busy outpatient clinic or
hospital ward, and uses a complicated 10-year
graded scale for age to calculate the score value
separately for patients with and without prior
stroke or TIA [38].
Adding in various biomarkers [e.g.,
biomarkers of cardiac function such as cardiac
troponin or N-terminal fragment B-type
natriuretic peptide (NT-proBNP)] [42, 43] or
various cardiac imaging modalities (e.g., left
atrial size, morphology and function, left atrial
fibrosis) [44] has been shown to improve the
predictive value of clinical risk factor based
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scores such as the CHA2DS2-VASc score, but
mainly by further substratification of high-risk
patients as identified by the ‘‘classic’’
CHA2DS2-VASc score. Since the CHA2DS2-VASc
C2 patients already have a clear indication for
OAC [20, 23, 24], further quantification of their
stroke risk would not really influence clinical
decision-making and is of little practical value.
Nevertheless, in selected AF patients without
‘‘classical’’ CHA2DS2-VASc stroke risk factors
(e.g., a 56-year-old man with a family history
of stroke) or those in whom the estimated risk
of bleeding apparently exceeds the risk of stroke
(e.g., in AF patients with a single additional
stroke risk factor and a prior bleeding event, or
taking dual antiplatelet therapy post acute
coronary syndrome), a refinement in stroke
risk assessment using biomarkers and/or
imaging modalities could possibly inform the
decision to use OAC. However, more research is
needed to define the biomarker cutoff values
and the time course of blood sampling which
would be informative for stroke risk assessment
in clinical practice [45].
Female sex-related risk of stroke in AF has
been extensively debated. In a large
meta-analysis, which included 30 studies with
a total of nearly 4.5 million participants, the
presence of AF in female individuals has been
associated with greater relative risk of stroke,
all-cause mortality, and cardiovascular
outcomes compared to men [46]. However, the
risk of stroke in women with AF has been shown
to be age-dependent. Whilst younger female
individuals with AF had similar or even lower
risk of stroke compared to their age-matched
male counterparts, elderly female AF patients
were at higher risk of stroke than the
age-matched male patients [47–51]. Possible
mechanisms of sex-related differences in the
risk of AF-related stroke are still not fully
elucidated [52].
Female sex has been assigned 1 point in the
CHA2DS2-VASc score [27]. Hence, a female AF
patient without additional CHA2DS2-VASc
stroke risk factors will have a score of 1, but
should be treated the same as male AF patients
with a CHA2DS2-VASc score of 0 [20, 24, 25].
These truly low risk AF patients (i.e., men with
CHA2DS2-VASc = 0 and women with
CHA2DS2-VASc = 1) have low annual stroke
rates of B1% [32, 53] and the use of
antithrombotic therapies in such patients has
been associated with a neutral or negative
relationship with stroke, bleeding, or death in
several large cohorts [54–57].
‘‘REAL-WORLD’’ RATES OF STROKE
IN NON-ANTICOAGULATED
PATIENTS WITH ATRIAL
FIBRILLATION AND ONE
ADDITIONAL STROKE RISK FACTOR
Figure 1 shows the annual rates of stroke in AF
patients without additional stroke risk factors
(i.e., with a CHA2DS2-VASc score of 0 [men] or 1
[women]) and in those with a single additional
stroke risk factor, as observed in various
real-world AF cohorts. In most of the studies
stroke rates are significantly increased with the
presence of one additional stroke risk factor in
non-anticoagulated AF patients.
Annual stroke rates in AF patients with a
single additional stroke risk factor observed in
these [37, 54, 56, 58–61] and other
observational cohorts [31, 33, 35, 57, 62–67]
are shown in Table 3. Overall, the stroke rates
ranged from 0.5% to 2.75%, or to 6.60% in the
study with the highest annual stroke rate
(Table 3). Such variability in stroke rates most
probably results from variable methodology,
anticoagulation status, and outcome
definitions in the studies [30, 68]. For
example, the study by Suzuki et al. was based
362 Adv Ther (2017) 34:357–377
on non-OAC use at baseline, but OAC status at
follow-up was unknown, such that the
unusually low stroke event rate could be
related to some high-risk patients being started
on OAC during follow-up [61].
Friberg et al. showed how variable duration
of ‘‘blanking period’’ influenced the observed
stroke rates (overall, the ischemic stroke rate
was 5.4% with no quarantine period, 3.0% with
1-week blanking period, and 2.8% with a
4-week quarantine, which was ultimately used
in that study) [66]. Although registry-based
studies generally require a quarantine period
(during which the events are not counted) to
achieve a stable population for long-term
follow-up, there is no room for a quarantine
period in clinical practice, because the decision
to use OAC should be made immediately upon
the documentation of AF rather than several
weeks or months later.
The event rate in the aforementioned study
by Friberg et al. was also influenced by the
definition of thromboembolic outcome—it was
doubled (from 0.5 to 0.7% to 1.3%) when the
outcome of ischemic stroke was combined with
non-specified stroke, transient ischemic attack
(TIA), or systemic embolism [66]. As a result of a
low annual rate of ischemic stroke among AF
patients with a single additional stroke risk
factor in that study (0.5%) the authors
questioned the benefit of OAC in such
patients, thus neglecting the importance of
reducing other AF-related outcomes such as
mortality or systemic embolism. In addition,
the study has been criticized for ‘‘conditioning
on the future’’, since all patients ever given OAC
(including the follow-up) were excluded from
the analysis, thus introducing a potential
selection bias leading to low event rates. The
same methodological flaws with ‘‘conditioning
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Fig. 1 Real-world stroke rates in AF patients with and
without a single additional stroke risk factor
[31, 33, 35, 41, 54, 56, 57, 59–61, 67, 129]. Komatsu
et al. and Suzuki et al. reported stroke rates based on no
OAC at baseline, but there was no record on whether
OAC treatment was started during follow-up (hence, the
reported stroke rates may be artificially low). Friberg et al.
and Aspberg et al. reported stroke rates only in AF patients
who were never prescribed OAC, starting from baseline
throughout the follow-up (i.e., a conditioning on the
future)
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Table 3 Rates of stroke in non-anticoagulated ‘‘real-world’’ AF patients with single additional stroke risk factor
Study Publication
year
Dataset N of events per N of
patients or patient-years
Annual event rate (95%
confidence interval)
Olesen et al.
[31]
2011 Danish nationwide administrative
databases
NR/14,526 2.01 (1.70–2.36)
Friberg et al.
[63]
2012 Swedish National Hospital
Discharge Registry
NR/6770 0.6 (NR)
0.9 (NR)
Friberg et al.
[56]
2012 Swedish National Hospital
Discharge Registry
63/10,500 PY 0.60 (0.45–0.77)
Komatzu
et al. [59]*
2012 A retrospective Japanese paroxysmal
AF cohort
1/210 PY 0.62 (0.00–3.23)
Larsen et al.
[60]
2012 The Prospective Danish Diet,
Cancer, and Health Cohort Study
25/2273 PY 1.10 (0.65–1.63)
Guo et al.
[33]
2013 The Chinese PLA General Hospital
medical database
NR/114 0.9 (NR)
Huang et al.
[58]
2014 The Hong Kong AF cohort 70/1061 PY 6.60 (5.09–8.29)
Forslund
et al. [64]
2014 The Stockholm (Sweden) AF
Database, n = 41,810
NR 0.5 (NR)
Chao et al.
[37]
2014 The National Health Insurance
research database in Taiwan
2312/110,854 2.09 (2.00–2.17)
Suzuki et al.
[61]*
2015 The Shinken database, J-RHYTHM
and Fushimi AF Registries
6/1096 PY 0.55 (0.04–1.23)
Olesen et al.
[62]
2015 Danish nationwide administrative
databases
697/40,023 PY 1.68 (1.46–1.94)
Chao et al.
[65]
2015 The National Health Insurance
research database in Taiwan
1858/67,673 PY (m)
1174/46,058 PY (f)
2.75 (2.62–2.87) m
2.55 (2.41–2.70) f
Lip et al.
[57]
2015 Danish nationwide administrative
databases
129/8573 1.50 (NR)
Friberg et al.
[66]
2015 The Swedish nationwide health
registries
NR/12,298 0.5 (NR)
van den
Ham et al.
[35]
2015 The Clinical Practice Research
Datalink database (UK)
130/16,800 PY 0.78 (NR)
Allen et al.
[67]
2016 Linked UK primary and secondary
healthcare databases
153/224,777 PY 0.6 (0.5–0.7)
364 Adv Ther (2017) 34:357–377
on the future’’ were apparent in the paper by
Aspberg et al. [41]. A more appropriate
assessment should be censoring on OAC
initiation, as reported by Nielsen et al. [69].
In another study, which used the outcome of
ischemic stroke or systemic embolism, the rates
of ischemic stroke and mortality in untreated
AF patients without additional stroke risk
factors were 0.43% and 3.87%, respectively,
whilst the rates in untreated AF patients with
a single additional stroke risk factor were 1.50%
(ischemic stroke) and 11.30% (death) [57].
Thus, the presence of a single additional stroke
risk factor in non-anticoagulated AF patients
was associated with a threefold increase in
1-year risk of stroke [hazard ratio (HR) 3.8;
95% confidence interval (CI), 2.61–5.63] and a
threefold increase in the risk of death (HR 3.23;
95% CI 2.87–3.63) in comparison to untreated
AF patients without additional stroke risk
factors [57].
A meta-analysis of seven large observational
studies yielded a 1.61% (0.00–3.23%) annual
risk of ischemic stroke in AF patients with one
additional stroke risk factor [53], which is
slightly below the 1.7% annual stroke risk
threshold for the use of VKAs but well above
the 0.9% cutoff for NOACs use [13]. The wide
confidence interval in that meta-analysis
resulted from considerable heterogeneity
among the studies. Nevertheless, removing the
study with the highest annual stroke risk of
6.60% from the meta-analysis [58] still yielded a
0.87% (0.28–1.46%) annual stroke risk, which
was still around the threshold for NOACs use.
Several studies showed that different stroke
risk factors within the CHA2DS2-VASc score carry
different weight with respect to stroke rates
[35, 58, 65, 70] (Table 4). In the study from
Taiwan, for example, stroke rates among AF
patients with a single additional stroke risk factor
varied from 1.91% with hypertension to 3.34%
with age of 65–74 years [65]. In all studies, age
has been consistently identified as the most
powerful single stroke risk factor among AF
patients with a CHA2DS2-VASc score of 1 (men)
or 2 (women). In Asian AF patients, the risk of
stroke substantially increased after the age of
50 years [71], and in a recent nationwide cohort
study of non-anticoagulated Taiwanese AF
patients with a single stroke risk factor in
addition to sex, even an age of 20–49 years was
associated with an annual rate of stroke of 1.33%
[72] (which is above the tipping point for NOACs
use).
Overall, despite some heterogeneity in the
statistical significance of the relationships of
various stroke risk factors with observed stroke
rates, the presence of a single CHA2DS2-VASc
stroke risk factor was associated with increased
Table 3 continued
Study Publication
year
Dataset N of events per N of
patients or patient-years
Annual event rate (95%
confidence interval)
Aspberg
et al. [41]
2016 The National Patient Register and
Prescribed Drug Register, Sweden
337/45,581.6 PY 0.7 (NR)
PY patient-years, NR not reported, UK United Kingdom, m male, f female
* Komatsu et al. and Suzuki et al. reported stroke rates based on no OAC at baseline, but there was no record on whether
OAC treatment was started during follow-up (hence, the reported stroke rates may be artificially low)
 Friberg et al. and Aspberg et al. reported stroke rates only in AF patients who were never prescribed OAC, starting from
baseline throughout the follow-up (i.e., a conditioning on the future)
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risk of ischemic stroke or a composite outcome
of stroke/systemic embolism/death in
observational AF cohort studies (Table 4).
Notwithstanding the discrepancies in
methodology, coagulation status, and the
characteristics of various AF populations, the
annual rates of stroke in AF patients with a
single additional stroke risk factor were around
or well above the contemporary threshold for
the initiation of OAC therapy, either with
well-controlled VKAs or, preferably, with
NOACs. Improvements in the management of
OAC therapy and better safety profile of
available OAC treatments coupled with the
data from contemporary AF cohorts facilitate
the use of OAC in this subset of AF patients.
EFFECTIVENESS OF OAC IN AF
PATIENTS WITH A SINGLE
ADDITIONAL STROKE RISK FACTOR
IN ‘‘REAL-WORLD’’
OBSERVATIONAL STUDIES
In the aforementioned Danish nationwide AF
cohort study, the use of warfarin in AF patients
with a single additional stroke risk factor
reduced their stroke risk to the level
comparable to AF patients with no additional
stroke risk factors (HR 1.33; 95% CI 0.76–2.33)
[57]. Also, the use of warfarin in AF patients
with a single additional stroke risk factor was
associated with reduction in stroke compared to
aspirin (HR 0.67; 95% CI 0.43–1.06) or no
therapy (HR 0.69; 95% CI 0.48–0.99), and
there was no increase in the bleeding rates
with warfarin relative to aspirin (HR 1.06; 95%
CI 0.78–1.43). The use of OAC was also
associated with significant reduction in
mortality in comparison to the use of aspirin
(HR 0.68; 95% CI 0.55–0.83) or no
antithrombotic therapy (HR 0.42; 95% CI
0.36–0.50) in these patients [57].
In a recent hospital registry-based study in
France, the use of OAC among AF patients with
no additional stroke risk factors was associated
with non-significant reduction in a composite
outcome of stroke, systemic embolism, or death
compared to no OAC therapy (HR 0.68; 95% CI
0.35–1.31, p = 0.25). However, the use of OAC
in AF patients with a single additional stroke
risk factor was clearly associated with significant
advantage in terms of reduction in stroke,
systemic embolism, or death compared with
no OAC therapy (HR 0.59; 95% CI 0.40–0.86,
p = 0.007) [70].
The evaluation of ultimate benefit of OAC
therapy in AF patients requires consideration of
both efficacy and safety of oral anticoagulant
drugs, since these drugs inevitably exert an
impact on hemostasis, thus increasing the risk
of bleeding events. The concept of net clinical
benefit (NCB) from OAC therapy represents a
balance of the prevention of AF-related
thromboembolic events against the risk of
bleeding with OAC, whereby the most serious
bleeding events (essentially ICH) have a greater
weight than ischemic strokes because of worse
outcome in terms of higher fatality or extensive
permanent disability associated with the
former. The first quantitative assessment of
such weighted NCB with warfarin treatment in
AF patients used the following formula: the
annual rate of ischemic stroke or systemic
embolism prevented by warfarin minus the
rate of OAC-related ICH multiplied by a factor
of 1.5, which was chosen arbitrarily [73]. A
similar concept and other approaches have
been subsequently used to estimate the NCB
of NOACs or VKAs or other antithrombotic
therapies in patients with AF [74–78].
An NCB analysis among AF patients with a
CHA2DS2-VASc score of C1 in the Danish
nationwide AF cohort yielded a neutral or
positive net clinical benefit with VKA therapy
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(the NCB with warfarin in patients with a
CHA2DS2-VASc score of 1 was neutral: 0.25
[95% CI -0.86 to 1.36]) [55] and a positive net
clinical benefit with NOACs (in patients with a
CHA2DS2-VASc score of 1 the NCB with
dabigatran 150 mg twice daily, for example,
was 1.36 [95% CI 0.86–2.58]) [54].
In the study of a community-based cohort of
unselected AF patients with one
non-gender-related additional stroke risk factor
[70], Fauchier et al. reported that the use of VKA
was associated with positive NCB in comparison
to no therapy (NCB 0.30; 95% CI 0.15–0.61, or
1.42; 95% CI 1.01–1.99, using the NCB
calculation method proposed by Singer et al.
[73] or Connolly et al. [79], respectively), or
aspirin (NCB 0.43; 95% CI 0.24–0.78, or 2.14;
95% CI 1.62–2.82), whilst the use of aspirin
yielded a negative NCB when compared to no
therapy (NCB -0.13; 95% CI -1.06 to -0.02, or
-0.72; 95% CI -1.50 to -0.34) [70]. The
Swedish AF cohort study also showed that the
use of OAC (VKAs) was associated with a
positive NCB in almost all AF patients,
excluding only those with a CHA2DS2-VASc
score of 0 at moderately increased risk of
bleeding; of note, in AF patients with a
CHA2DS2-VASc score of 1, the NCB was 0.30;
95% CI 0.10–0.40 [56].
Although VKA therapy is generally very well
managed in Sweden in comparison to many
other countries [80], the treatment effect of
NOACs compared with VKA for the prevention
of stroke and systemic embolism seems
consistent regardless of cTTR [81], related to
the observation that there is no significant
change in rate of major bleedings across center
average TTR and individual TTR quartiles
[82, 83]. Moreover, well-managed VKA therapy
with a TTR of C70% is often difficult to
maintain in clinical practice, as shown in
many registry-based studies [84, 85] or even in
randomized clinical trials [86]. Even though the
median TTR was 73%, a TTR of C70% was
achieved in only 55% of the patients [87]. Thus,
NOACs may be preferred over VKAs in many
clinical circumstances, provided that a good
adherence to therapy can be accomplished. An
increasing body of evidence suggests that the
performance of NOACs in real-world settings is
broadly similar to their efficacy and safety in the
respective randomized clinical trial [88–106].
The outcomes of VKA therapy are highly
dependent on the quality of anticoagulation, as
measured by individual patient’s TTR [84], and
OAC-naive patients are particularly vulnerable
to OAC-related serious adverse events (both
thromboembolism and bleeding) in the first
months of treatment, during the OAC inception
period [107]. The SAMe-TT2R2 score, assigning 1
point each to female sex, age of \60 years,
history of two or more comorbidities (i.e.,
hypertension, diabetes mellitus, coronary
artery disease/myocardial infarction, peripheral
arterial disease, congestive heart failure,
previous stroke, pulmonary disease, and
hepatic or renal disease) and treatment with
drugs interacting with VKAs (e.g., amiodarone)
and 2 points each for current or recent tobacco
use and non-Caucasian ethnicity, has been
shown to have reasonably good predictive
ability to identify OAC-naive AF patients who
would do well on VKAs (patients with a
SAMe-TT2R2 score of 0–2), whilst those with a
SAMe-TT2R2 score of[2 should be prescribed a
NOAC [108]. The SAMe-TT2R2 score has been
shown to be predictive not only of the quality
of anticoagulation with VKAs but also of
all-cause mortality and composite endpoint of
thromboembolic events, major bleeding, and
mortality [109–114].
Given the superior safety of NOACs relative
to VKAs in terms of reduced risk of ICH and the
advantage of more convenient use in
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comparison to VKAs, NOACs should be
considered as the first-line antithrombotic
treatment option in most patients with AF and
a single additional stroke risk factor.
Alternatively, particularly in case of a
restricted reimbursement policy, the choice
between NOACs and VKAs could be guided by
the SAMe-TT2R2 score. Thus, patients with a
SAMe-TT2R2 score of 0–2 would potentially do
well on VKAs, whilst those with a SAMe-TT2R2
score of [2 are less likely to do well on VKA,
unless additional measures such as more
regular/frequent follow-up, INR checks and
counselling should be given, or these days, a
NOAC.
PATIENT VALUES
AND PREFERENCES
Although OAC therapy achieves the greatest
absolute reduction of stroke risk in AF patients
at highest risk of stroke, AF patients at ‘‘low to
moderate’’ risk of stroke still have a clear
positive net clinical benefit from OAC therapy
(particularly with NOACs). Nevertheless, in a
recent Canadian combined survey on
physicians and AF patients [115] the fear of
OAC-related major bleeding complications has
been ranked as the highest-priority OAC
therapy-related consideration by physicians,
whilst it was placed at only 5th position by
patients (of note, patients were more concerned
with interactions of OAC with food and drugs,
possibility of rapid reversal of OAC effect in
emergency situations, the clinical experience
with particular OAC, or the requirement for
regular blood testing). Another study using an
iPad-facilitated questionnaire revealed that AF
patients were willing to suffer four major
bleeding events in exchange for preventing
just one stroke and, in their view, the
treatment threshold for the acceptance of OAC
therapy was a minimum absolute stroke risk
reduction of 0.8% per year (a number needed to
treat 125 AF patients) [116].
Moreover, all health-related quality of life
(QoL) scores (SF36) in a recent study were found
to be significantly lower in warfarin-treated
versus the NOAC-treated patients, which may
be explained by the higher bleeding rates and
hospital admissions while on warfarin
treatment [117].
Recent survey among European
electrophysiology centers showed that
practicing European cardiologists were
spending a considerable amount of time
discussing individual risk profiles and available
therapies with their AF patients [118]. In a
randomized trial, educational interventions in
AF patients resulted in improved quality of oral
anticoagulation with VKAs [119]. Engaging AF
patients in the informed shared decision-making
about OAC therapy (either VKAs or NOACs)
facilitates their understanding of treatment and
helps in eliciting (and correcting) their possible
misperceptions or personal barriers to OAC
treatment, thus improving their adherence to
therapy and ultimate treatment effects
[120, 121]. A questionnaire-based tool
facilitating the identification of patients’ values
and preferences and supporting the decision
regarding the use of VKAs or NOACs has been
described [122].
Importantly, the individual risk profile of AF
patients initially presenting as a ‘‘borderline’’ or
‘‘moderate’’ risk category may change over time
[123]. Regular clinical follow-up of these
patients and periodical re-assessment of
individual patient risk profile are mandated,
since aging and/or development of cardiac,
renal, or other comorbidities may aggravate
the patient’s stroke or bleeding risk [124], which
could sometimes require adjustments in OAC
treatment with respect to the choice of oral
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anticoagulant drug and appropriate dosing
[125].
CONCLUSION
Patients with non-valvular AF and a single
additional stroke risk factor may be denied
OAC because of the misperception that their
risk of stroke is not sufficiently high to justify
the use of OAC (either VKAs or NOACs).
Observational data from real-world AF cohorts
show that the annual stroke rates in such
patients are higher than in patients with no
additional stroke risk factors and are around or
well above the contemporary threshold for OAC
treatment. Well-controlled VKA or NOACs
therapy in these patients has been associated
with a positive net clinical benefit owing to
reduction in the risk of stroke, systemic
embolism, or death in comparison to no
therapy or aspirin, with no increase in the risk
of bleeding relative to aspirin.
Given the superior safety and convenience of
NOACs relative to VKAs, NOACs should be
considered as the first-line antithrombotic
treatment option in most AF patients with a
single additional stroke risk factor. Regular
clinical follow-up and periodical re-assessment
of individual patient risk profile are mandated,
since aging and/or development of cardiac,
renal, or other comorbidities may aggravate
the patient’s stroke or bleeding risk.
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